Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Acorda Therapeutics Inc ACORQ

Healthcare Biotechnology
Acorda Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. The Company markets Inbrija (levodopa inhalation powder), which is approved in the United States for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson’s disease treated with carbidopa... see more

Recent & Breaking News (OTCPK:ACORQ)

Forward Pharma Falls On Biogen Patent Victory Over MS Drug Ingredient

Benzinga.com  March 31, 2017

Acorda Announces Long-Term Safety Data for CVT-301

Business Wire March 29, 2017

The Growth of the Regenerative Medicines Market

PR Newswire March 28, 2017

Research Reports Initiation on Biotech Stocks -- Radius Health, Acorda, PhaseRx, and Athersys

PR Newswire March 22, 2017

Acorda Launches Alexa Skill in Conjunction with MS Awareness Month

Business Wire March 13, 2017

Patent Trials and Appeal Board (PTAB) Upholds Four AMPYRA® Patents

Business Wire March 9, 2017

Watch These 7 Huge Put Purchases In Monday Trade

Benzinga.com  March 6, 2017

Acorda to Present at the Cowen and Company 37th Annual Healthcare Conference

Business Wire February 27, 2017

Catherine D. Strader, Ph.D., Joins Acorda Therapeutics Board of Directors

Business Wire February 21, 2017

Acorda Provides Financial and Pipeline Update for Fourth Quarter and Year End 2016

Business Wire February 14, 2017

Watch These 5 Huge Put Purchases In Friday Trade

Benzinga.com  February 10, 2017

Acorda Announces Positive Phase 3 Clinical Trial Results for CVT-301

Business Wire February 9, 2017

Acorda Therapeutics to Present at Two Investor Conferences in February

Business Wire February 3, 2017

Acorda to Host Conference Call to Discuss Fourth Quarter 2016 on February 14, 2017

Business Wire January 31, 2017

Research Reports Initiation on Biotech Stocks -- Jazz Pharma, Infinity Pharma, Acorda Therapeutics, and Ultragenyx Pharma

PR Newswire January 30, 2017

Acorda Announces 2016 AMPYRA Net Sales and 2017 Financial Guidance at J.P. Morgan Healthcare Conference

Business Wire January 9, 2017

January Will Feature Some Of The Market's Most Influential Events

Benzinga.com  December 30, 2016

Acorda Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference

Business Wire December 28, 2016

12 Biggest Mid-Day Losers For Monday

Benzinga.com  December 19, 2016

Biotech Stocks on Investors' Radar -- Northwest Biotherapeutics, ACADIA Pharma, Acorda Therapeutics, and Ultragenyx Pharma

PR Newswire December 5, 2016